Syngene plans to scale up for biologics

Syngene, an arm of Biocon, is expanding its capital investment as it waits to complete a 40-acre, $100-million research facility in Mangalore.
Source: The Economic Times - Category: Consumer Health News Source Type: news
More News: Health